Skip to main content
Studies see potential for cancer risk in CRISPR-Cas9 therapies

Scientists from Sweden's Karolinska Institute and Britain's Cambridge University said more studies are needed to determine if the use of CRISPR-Cas9 gene-editing technology could raise the risk of cancer developing due to potential malfunction of the p53 gene. Their research papers were published in the journal Nature Medicine.

Full Story: